Exhibit 99.1 Corporate Presentation April 2024

2 Disclaimers This presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Abpro Corporation (“Abpro”) and Atlantic Coastal Acquisition Corp. II (“ACAB”) and related transactions (the “Proposed Business Combination”) and for no other purpose. No representations or warranties express or implied are given in or respect of this Presentation. To the fullest extent permitted by law in no circumstances will Abpro, ACAB or any of their respective subsidiaries stockholders affiliates representatives partners directors officers employees advisers or agents be responsible, or liable for any direct indirect or consequential loss or loss of profit arising from use of this Presentation its contents its omissions reliance on the information contained within it or on opinions communicated in relation thereto or otherwise arising in connection therewith. This Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of Abpro or the Proposed Business Combination. Viewers of this Presentation should each make their own evaluation of Abpro and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws with respect to the Proposed Business Combination, including statements regarding the benefits of the Proposed Business Combination, the anticipated timing of the Proposed Business Combination, the products and services offered by Abpro and the markets in which it operates and Abpro’s projected future results. These forward-looking statements generally are identified by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions, and as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Presentation, including but not limited to: (i) the risk that the Proposed Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of ACAB’s securities; (ii) the risk that the Proposed Business Combination may not be completed by ACAB’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by ACAB; (iii) the failure to satisfy the conditions to the consummation of the Proposed Business Combination, including the receipt of the requisite approvals of ACAB’s and Abpro’s stockholders, the satisfaction of the minimum trust account amount following redemptions by ACAB’s public shareholders and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third party valuation in determining whether or not to pursue the Proposed Business Combination; (v) the occurrence of any event change or other circumstance, that could give rise to the termination of the agreement and plan of merger; (vi) the effect of the announcement or pendency of the Proposed Business Combination on Abpro’s business relationships, performance and business generally; (vii) risks that the Proposed Business Combination disrupts current plans of Abpro and potential difficulties in Abpro’s employee retention as a result of the Proposed Business Combination; (viii) the outcome of any legal proceedings that may be instituted against Abpro or against ACAB related to the agreement and plan of merger or the Proposed Business Combination; (ix) the ability to maintain the listing of ACAB’s securities on The Nasdaq Stock Market LLC; (x) the price of ACAB’s securities may be volatile due to a variety of factors including changes in the competitive and regulated industries in which Abpro plans to operate, variations in performance across competitors, changes in laws and regulations affecting Abpro’s business and changes in the combined capital structure; (xi) the ability to implement business plans forecasts and other expectations, after the completion of the Proposed Business Combination and identify and realize additional opportunities; (xii) the enforceability of Abpro’s intellectual property rights including its copyrights patents trademarks and trade secrets and the potential infringement on the intellectual property rights of others; (xiii) risks related to Abpro’s ability to achieve and maintain profitability and generate cash; (xiv) costs related to the Proposed Business Combination and the failure to realize anticipated benefits of the Proposed Business Combination or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xv) the potential inability of Abpro to manage growth effectively; (xvi) Abpro’s dependence on senior management and other key employees; (xvii) risks related to general economic conditions, including demand, interest rates, inflation, supply chains and the effect of the conflicts in Ukraine and the Middle East; (xviii) cyberattacks on ACAB’s or Abpro’s information technology systems; (xix) the ability to attract and retain staff with the skills and expertise needed; (xx) increases in the cost of labor and research and development; (xxi) the effects of natural disasters, adverse weather conditions or public health crises; geopolitical, economic and climate-or weather-related risks in regions with a significant concentration of Abpro’s operations; (xxii) the inability to successfully bring Abpro’s products to market (including obtaining regulatory approval); and (xxiii) the early termination of any of Abpro’s existing agreements to develop its products; (xxiv) the acceptance and efficacy of Abpro’s products; (xxv) damage to Abpro’s reputation through the actions or inactions of third parties; investigative or legal actions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of ACAB’s Registration Statement on Form S-1 filed on December 2, 2021 (as amended), ACAB’s Annual Report on Form 10-K for the year ended December 31, 2022, ACAB’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, the Registration Statement (as defined below) and the proxy statement/prospectus to be contained therein and the other documents filed by ACAB from time to time with the U.S. Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements and Abpro and ACAB assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Abpro nor ACAB gives any assurance that either Abpro or ACAB respectively will achieve its expectations.

3 Disclaimers Additional Information and Where to Find It This document relates to the Proposed Business Combination between Abpro and ACAB. ACAB filed a registration statement on Form S-4 relating to the Proposed Business Combination (the “Registration Statement”) which will includes a proxy statement/prospectus of ACAB. The proxy Statement/prospectus will be sent to all ACAB and Abpro stockholders. ACAB will also file other documents regarding the Proposed Business Combination with the SEC. Before making any voting decision, investors and security holders of ACAB and Abpro are urged to read the Registration Statement, the proxy statement/prospectus contained therein, and all other relevant documents filed or that will be filed with the SEC in connection with the Proposed Business Combination as they become available because they will contain important information about the Proposed Business Combination. Investors and security holders will be able to obtain free copies of the proxy Statement/prospectus and all other relevant documents filed or that will be filed with the SEC by ACAB through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by ACAB may be obtained free of charge by written request to ACAB at Atlantic Coastal Acquisition Corp. II, 6 St. Johns Lane, Floor 5, New York, New York, 10013 Participants in Solicitation ACAB and Abpro and their respective directors and officers may be deemed to be participants in the solicitation of proxies from ACAB’s stockholders in connection with the Proposed Business Combination. Information about ACAB’s directors and executive officers and their ownership of ACAB’s securities is set forth in ACAB’s filings with the SEC, including ACAB’s Registration Statement on Form S-1 filed with the SEC on December 2, 2021. To the extent that holdings of ACAB’s securities have changed since the amounts printed in ACAB’s Registration Statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the Proposed Business Combination may be obtained by reading the proxy Statement/prospectus regarding the Proposed Business Combination when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph. Industry and Market Data This presentation has been prepared by Abpro and ACAB and includes market data and other statistical information from sources believed by Abpro and ACAB to be reliable, including independent industry publications, governmental publications or other published independent sources. Some data is also based on the good faith estimates of Abpro or ACAB, which in each case are derived from its review of internal sources as well as the independent sources described above. Although Abpro and ACAB believe these sources are reliable, Abpro and ACAB have not independently verified the information and cannot guarantee its accuracy and completeness. Financial Information; Non-GAAP Financial Measures The financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in or may be presented differently in the Registration Statement to be filed by ACAB with the SEC and the proxy Statement/prospectus contained therein. Certain measures in this presentation do not have any standardized meaning as prescribed by Generally Accepted Accounting Principles (“GAAP”) in the United States and, therefore, are considered non-GAAP measures. These measures may not be comparable to similar measures presented by other companies and should not be viewed as a substitute for measures reported under U.S. GAAP. These measures are commonly used by Abpro and ACAB to provide shareholders and potential investors with additional information regarding Abpro’s or ACAB’s liquidity and their ability to finance their operations. You should review Abpro’s audited financial statements, which will be included in the Registration Statement. Please see the Appendix for the accompanying non-GAAP reconciliations. No Offer or Solicitation This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended. Use of Projections This Presentation contains projected financial information with respect to Abpro and ACAB. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See “Forward-Looking Statements” above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such forecasts are achieved. Trademarks Solely for convenience, the trademarks, trade names and service marks may appear in this presentation without the ® and symbols, but any such references are not intended to indicate, in any way, that we forgo or will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners.

44 Transaction Overview Investment Highlights 1 2 Pipeline and Technology Experienced Team 3 4 Platforms Table of Lead Candidates Additional Pipeline Contents 5 6 Candidates Program Development Appendix 7 8 Timeline

5 5 Key Presenters Miles Suk Shahraab Ahmad Ian Chan CEO CEO & Co-Founder Board Member Atlantic Coastal Acquisition Abpro Corporation Abpro Corporation Corp. II (ACAB)

6 Transaction Overview Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) plans to conduct a Pro Forma Valuation at Close business combination with Abpro Corporation (“Abpro“) at a purchase price of approximately $500 million (USD millions, except for share data) • Transaction expected to be funded through a combination of $37.6 million Pro-Forma Shares Outstanding 49.8m PIPE financing and an estimated $7.2 million ACAB cash in trust Share Price $10.00 • 100% equity rollover by Abpro shareholders, representing an expected ~78% Pro-Forma Equity Value $498.1 of the Pro Forma Equity Value • Net proceeds are expected to fund operations of Abpro, including R&D efforts and clinical development of two lead programs (-) Cash to Balance Sheet $38.8 • Targeted transaction close is expected Q2 2024, subject to customary closing Pro-Forma Enterprise Value $459.3 conditions and approvals Illustrative Pro Forma Ownership Sources & Uses Sources (USD millions) 2.3% Abpro Equity Rollover $388.8 78.1% 1.3% Cash in Trust $7.2 3.6% Abpro Existing Shareholders 7.1% PIPE Financing $37.6 7.5% 7.5% PIPE Investors Total Sources $433.6 Sponsor Shares 7.1% Uses (USD millions) Other Shareholders 3.6% 78.1% Abpro Equity Rollover $388.8 Service Providers 2.3% Cash to Balance Sheet $38.8 1.3% ACAB Existing Shareholders Estimated Transaction Fees $6.0 Total Uses $433.6

7 Investment Highlights Proprietary Antibody Platform Robust Therapeutic Pipeline of Next Generation Candidates ® • Antibody Discovery: DiversImmune Candidate Indication TM • Antibody Engineering: MultiMab • ABP-102(HER2/CD3) Breast and gastric cancer • ABP-201(VEGF/ANG2) Wet AMD and DME • ABP-110(GPC3/CD3 ) Liver cancer • ABP-150(Claudin18.2/CD3) Gastric cancer Development & Commercialization Experienced Leadership Team and World Partnerships Established Class Boards • Celltrion, Inc. (KRX: 068270)• Industry leaders with wealth of experience from top industry organizations • Fully funding development of ABP-102 • Up to $1.75B in total payments to Abpro • Team with extensive biotechnology experience 1 • Abpro Bio • Nanjing Chia -Tai Tianqing Pharmaceutical 1 Abpro Bio Co. Ltd (KOSDAQ: 195990), through its subsidiary Abpro Bio International, Inc.,

8 Experienced Leadership Team Christian Zapf, JD, MBA Richard Mitrano Ian Chan, MBA Eugene Chan, MD Robert Markelewicz, MD SVP of Corporate Development SVP of Finance CEO, Co-founder Chairman, Co-founder Chief Medical Officer & General Counsel Brown AB; Harvard MBA Harvard AB; Harvard MD Brown ScB, MMSc, MD Cambridge AB; Columbia JD; Bentley ScB INSEAD MBA

9 Atlantic Coastal Management Team Shahraab Ahmad Burt Jordan Jason Chryssicas Tony Eisenberg President Chairman, CEO CFO CSO

10 10 Experts on Boards 1 2 2 Robert Langer, PhD Laurie Glimcher, MD Ron Levy, MD David H. Koch Institute Professor, MIT; President and CEO, Professor and Chief, Founder of Moderna, BIND, Dana-Farber Cancer Institute Division of Oncology, Momenta, AIR, others Stanford School of Medicine 2 2 2 George Tsokos, MD Shiv Pillai, PhD Steven Schnittman, MD, PhD Professor of Medicine, Professor of Medicine, Harvard Infectious Disease Specialist; Beth Israel Deaconess Medical School and Massachusetts Ex-NIH/Chief HIV Division; Medical Center General Hospital Ex-VP BMS 1. Board of Directors member 2. Scientific Advisory Board member

11 Pipeline with Next Generation Candidates TOTAL INDICATION PROGRAM TARGET PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 PHASE 3 ADDRESSABLE MARKET 1 DME/Wet AMD Anti-VEGF/ANG2 ABP-201 $10.4 Billion Breast, Gastric 2 Anti-HER2/CD3 ABP-102 $12.1 Billion Cancer 3 Liver Cancer Anti-GPC3/CD3 ABP-110 $12.9 Billion 4 Gastric Cancer Anti- CLAUDIN18.2/CD3 ABP-150 $13.11 Billion 1 Prescient and Strategic Intelligence, Wet Age-Related Macular Degeneration Market Overview, March 2019. 2 Research and Markets, Global HER2+ Breast Cancer Market Will Expand to 12.1 Billion in 2030, September 21, 2021. 3 SNS Insider, Liver Cancer Therapeutics Market to Surpass USD 12,910.02 Million by 2030 Driven by Rising Incidence of Liver Cancer and Advancements in Early Diagnosis, October 25, 2023. 4 Data Bridge Market Research, Global Gastric Cancer Market - Industry Trends and Forecast to 2029, September 2022.

TECHNOLOGY PLATFORM

® 13 13 Diversimmune Discovery Platform Features: • Rapid Generation Creates antibody therapies against traditionally Proprietary antibody discovery platform difficult targets that seeks to swiftly produce a diverse array of antibodies Validated by global pharma and research institutions • Target Variety Proven in 300+ campaigns during early years of Targets both clinically validated and novel targets development • Overcoming Challenges Targets traditionally difficult-to-access antigens Preclinical results Immunization published in: • Drug-Like Properties Key role in SAP program via Seeks to ensure generated antibodies platform for GSK SAP amyloid Optimization possess characteristics conducive to program in Phase 2 therapeutic development • Create “Building-Blocks” Diversification Seeks to deliver functional antibody building blocks with exceptional affinity and specificity to address disease- specific challenges

TM 14 14 MultiMab Antibody Engineering Platform and TetraBi Format Anticipated Advantages of TetraBi Format: 1 Enhancing efficacy and safety: fine-tuning antibody product • Bivalent binding to TAA for potentially formats for optimal results increased efficacy • Fc modification for reducing toxicity and increasing antibody half life • Flexible configuration for increased safety and/or maximized efficacy • Symmetrical structure for streamlined manufacturing 1 TAA= Tumor-Associated Antigen

LEAD PROGRAMS • ABP-102 • ABP-201

ABP-102 HER2/CD3 T-Cell Engager Treatment for HER2+ Breast Cancer & Gastric Cancer

17 17 ABP-102: Strategic Partnership Global Development & with Celltrion Commercialization Partnership Highlights Leading biopharmaceutical company headquartered in Incheon, South Korea; KRX: 068270 Fully Funded Anticipated Development Plan • Celltrion funds all development costs, including preclinical and • Investigational New Drug (IND) enabling studies underway clinical studies • 1H 2025: File IND application • 2H 2025: Initiate Phase 1/2 clinical trial $1.75B • Abpro to receive payments up to Indication: $1.75B, including equity Progressive HER2+ Breast and Gastroesophageal Adenocarcinomas investment, development/commercial Design: milestone payments First-In-Human, multicenter, open-label, single-agent, Phase 1/2 trial 1 50% • Abpro retains a 50% share of profits worldwide 1 The proceeds from commercialization are subject to a 50/50 profit split. Amounts that may be paid by third party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization partners, are also subject to a 50/50 split. Following commercial approval of ABP-102, we have agreed to reimburse Celltrion 87.5% of its direct and certain indirect costs and expenses incurred through first commercial sale. Celltrion is entitled to offset amounts otherwise due to us under the agreement until our share of these costs has been paid back; provided that we are entitled to a minimum 25% of profit from commercial sales and from third party collaborators regardless of the amount of unreimbursed development costs outstanding (and then 50% once the reimbursement has been made in full). In addition, we are entitled to up to over $1.75 billion in development and sales milestones. We are responsible for world-wide patent prosecution, with Celltrion reimbursing 50% of our out-of-pocket costs.

18 Potential benefits of Potential Competitive ABP-102 in immuno- Advantages: Addressing Unmet oncology Needs in HER2+ • Activating T cells to kill tumor cells • Current HER2-directed therapies have Cancers Treatment: demonstrated increased chemical off TetraBi antibody targets HER2 on target toxicity (e.g. TKIs and ADCs) tumor cells and CD3 on T cells ABP-102 Competitive and/or reduced efficacy from drug resistance or limited potency Landscape • Reduce activity on -low or negative requiring combination with HER2 cells for safety chemotherapy (i.e.: mAbs), especially selectively targets HER2-high and in the relapsed and refractory disease intermediate expressing cells population • May improve clinical efficacy • ABP-102 was designed to overcome $12.1 billion by inducing T cell infiltration into these challenges as a single-agent HER2+ tumors, potentially targeting Projected global HER2+ market size by therapy that potently engages the 1 various solid tumors with HER2 2030 patient’s natural immune system overexpression. without toxic chemicals to directly target and destroy the tumor • Enhances binding, selectivity for Development Fully Funded tumor cells, potency, and By collaboration partner Celltrion therapeutic index with Dual HER2 binding sites

HER2 19 19 ABP-102: Next generation T-cell engager for HER2+ solid tumors HER2-high CD3 (Humanized and Cyno Cross-Reactive) Key Characteristics: • Dual-arm affinity-tuned construct for selective killing and cytokine release on HER2-high target cells, with reduced killing and cytokine release on HER2-low target cells to reduce “on- target, off-tumor” toxicity • Bivalent HER2 binding to promote more selective HER2-high target cell engagement HER2-low TM • TetraBi IgG-[L]-scFv format with functionally monovalent CD3 binding at the hinge region to prevent T cell activation in the absence of tumor cells • Cross-reactivity to human and cynomolgus CD3 for toxicity assessment • Engineered for reduced Fc receptor engagement • Symmetrical structure with natural antibody features for efficient manufacturing and a potentially improved dosing Abpro internal data profile

ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODY Treatment for Diabetic Macular Edema (“DME”) & Wet Age-related Macular Degeneration (”AMD”)

21 21 Addressing Unmet Needs in Wet AMD/DME Treatment: ABP-201 • We believe that ABP-201 will Competitive Landscape require less frequent dosing, providing a significant $10.4 billion advantage in the commercial Global Wet AMD market setting. 1 size projection in 2024 • We anticipate that ABP-201 will not suffer from drug Potential Competitive Advantages: resistance to the same extent as drugs that target VEGF • Unlike Eylea and Lucentis, ABP-201 seeks to inhibit both alone, as increased signaling VEGF and ANG-2 by ANG-2 in response to anti- • Unlike Vabysmo, ABP-201 has two binding sites for VEGF VEGF therapy is one of the and ANG-2, designed to more effectively trap each ligand primary mechanisms of resistance to VEGF inhibitors. • ABP-201 has a longer half-life in the eye than Eylea, which contributes to pharmacological durability 1. Prescient and Strategic Intelligence, Wet Age-Related Macular Degeneration Market Overview, March 2019. 2. Risk-adjusted revenues for ABP-201; Does not account for costs Source: Health Advances model and analysis

22 ABP-201: Anti-VEGF/ANG2 Target Indication: Wet AMD/DME Key Characteristics • Dual inhibition of VEGF and ANG-2 to block angiogenesis ABP-201 • Four high-affinity binding sites for increased potential potency • Dual targeting in single molecule for simultaneous inhibition • Natural antibody structure for potentially improved dosing • Symmetrical structure for efficient manufacturing Ligand trap targeting VEGF and ANG-2 for vascular diseases of the eye • Formulated for intravitreal injection • Designed to block blood vessel formation and normalize damaged vessels through co-targeting vascular endothelial growth factor, or VEGF, and Vabysmo angiopoietin-2, or ANG-2

23 ABP-201: Positive Results in Preclinical Models Mean total ocular examination scores over 1 Mean Intraocular pressure over time 1 time ABP-201 does not induce significant inflammation or intraocular pressure increases in preclinical models OE Scores range from 0(no abnormalities) to a maximum of 48 2 Laser-induced neovascularization model in rats Day 15 ABP-201 significantly reduced vascular lesions comparable to Eylea in preclinical models 1 PoweredResearch, Safety, Tolerability, and Pharmacokineti C Study Following Intravitreal (IVT) Delivery of a Novel Compound in Rabbit, April 27, 2021. 2 Ora, Inc., CNV Study with Intravitreally-injected Abpro Test Article ABP201 in Brown Norway Rats, December 20, 2023. Lesion volume Leakage score

24 24 Current Status: • Investigation New Drug (IND) enabling studies underway Anticipated Development Plan • Q1 2026: File IND application and Initiate a Phase 1 trial in patients with ABP-201 Wet AMD Development • Following the identification of the Collaboration Highlights: Strategy maximum tolerated dose (MTD) in Phase 1, a larger randomized Phase 2 dose ranging trial to be conducted • Co-development via a territorial 1 partnership with Abpro Bio • Abpro retains U.S. and European Union Five commercial rights 1. Abpro Bio Co. Ltd (KOSDAQ: 195990), through its subsidiary Abpro Bio International, Inc., holds territory rights primarily in Asia and Middle East, and is an equity investor of Abpro Corporation.

ADDITIONAL T-CELL ENGAGERS ABP-150: Anti-Claudin 18.2/ CD3 against Gastric Cancer ABP-110: Anti-GPC3/CD3 against Liver Cancer

26 ABP-150: Anti-Claudin18.2/CD3 Target Indication: Gastric Cancer $13.11 billion Key Characteristics • T-cell engager designed to fight cancer through co-targeting CD3 & Claudin 18.2 Global gastric cancer market 2 size projection by 2029 • Specific for Claudin 18.2, avoiding binding closely related isoform Claudin 18.1 expressed in the lung. • Showed potent killing in in vitro T cell-mediated killing assays in preclinical studies • Showed potent efficacy in in vivo efficacy models • Well tolerated in preclinical efficacy models Claudin18.2 Claudin 18.2 Claudin 18.2 Collaboration with Nanjing Chia-Tai ABP-150 1 Tianqing Pharmaceutical • Technology access fee and R&D funding up to CMC stage reimbursed by NJCTTQ • Abpro has potential to receive milestone payment up to $405 million USD • Abpro retains commercialization rights outside China and Thailand 1 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd is a pharmaceutical company specializing in research and development, production and commercialization of drugs for cardiovascular diseases, tumors, perioperative care, gastrointestinal disorders and urologic diseases headquartered in Nanjing, China 2 Data Bridge Market Research, Global Gastric Cancer Market - Industry Trends and Forecast to 2029, September 2022.

27 ABP-150: in vivo Efficacy and Safety Profile in Preclinical Models 1 Potent in vivo efficacy in gastric cancer ABP-150 is well tolerated in a preclinical tox model 1 xenograft mouse model Body weights Temperatures 24 38.0 ABP-150 17 mg/kg ABP-150 17 mg/kg ABP-150 1.7 mg/kg ABP-150 1.7 mg/kg 37.5 22 ABP-150 0.17 mg/kg ABP-150 0.17 mg/kg Vehicle Vehicle 2500 37.0 0.05 mg/kg ABP-150 20 36.5 0.005 mg/kg ABP-150 2000 18 Vehicle control (PBS) 36.0 1500 Body weights 16 35.5 0 20 40 60 0 20 40 60 24 ABP-150 17 mg/kg 1000 Study Day Study Day ABP-150 1.7 mg/kg 22 ABP-150 0.17 mg/kg IL-6 500 Food consumption Vehicle 200 20 20 ABP-150 17 mg/kg 0 0 10 20 30 ABP-150 1.7 mg/kg 18 15 ABP-150 0.17 mg/kg Study Day Vehicle 16 100 10 0 20 40 60 Study Day 5 NUGC-4 tumor cells mixed with human PBMCs and implanted 0 0 subcutaneously in the same bolus into NSG mice. 0 20 40 60 0 10 20 500 1000 1500 Study Day Hours Representative toxicity data from human CD3-transgenic mouse model. In this model, ABP-150 can bind both the transgenic human CD3 on mouse T cells and mouse claudin 18.2 on gastric epithelial cells. Upper left: Body weight measurements over time. No significant decrease in body weight with ABP-150 administration. Lower left: Amount of food consumed over time. No differences in food consumption between ABP-150-treated animals and placebo controls. 1 Abpro internal data. Upper right: Body temperatures over time. No fever response with ABP-150 treatment. Lower right: IL-6 levels in blood over time. ABP-150 administration does not significantly increase IL-6, a major cytokine associated with triggering cytokine release syndrome (CRS). 3 Tumor volume (mm ) Body Weight (g) Grams Body Weight (g) Body temperatures (°C) Serum cytokine (pg/mL)

28 28 ABP-110: Anti-GPC3/CD3 Target Indication: Hepatocellular Carcinoma- Liver Cancer Designed to provide in-vitro T-cell + 2 + 2 HEP3B tumors + CD8 T cells HEPG2 tumors + CD8 T cells dependent cellular cytotoxicity 60 100 (TDCC) against liver cancer cells YP7 x CD3 YP7 x CD3 80 3BN9 x CD3 3BN9 x CD3 40 • Showed high TDCC in both GPC3-expressing 5V2A x CD3 5V2A x CD3 60 HepG2 and Hep3B cell lines in preclinical Isotype x CD3 Isotype x CD3 models 40 20 • Elicited stronger TDCC compared to original 20 YP7 x CD3 bispecific in preclinical models 0 0 -20 Concentration (nM) -20 Concentration (nM) $12.9 billion Global liver cancer market size • YP7 is originally in-licensed from NIH at early stage 1 projection by 2030 • 3BN9 x CD3 and 5V2A x CD3 are Abpro’s improved BsAbs 1 SNS Insider, Liver Cancer Therapeutics Market to Surpass USD 12,910.02 Million by 2030 Driven by Rising Incidence of Liver Cancer and Advancements in Early Diagnosis, October 25, 2023. 2 Abpro internal data 0.0001 0.001 0.01 0.1 1 10 100 0.0001 0.001 0.01 0.1 1 10 100 %cytotoxicity %cytotoxicity

29 Anticipated Clinical Development Timeline Timeline 2025 2026 2026 2027 2027 2028 2028 2029 2029 2030 2030 2031 and Beyond 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H ABP-102 BLA Phase 1 Phase 2 Phase 3 BLA- ABP-201 Phase 1 Phase 2 Phase 3 2034 1H BLA- ABP-150 Phase 1 Phase 2 Phase 3 2032 2H BLA- ABP-110 Phase 1 Phase 2 Phase 3 2032 2H Anticipated Upcoming GLP-Tox Study IND-Enabling Study Completion Completion Milestones ABP-102 2Q 2024 1Q 2025 ABP-201 4Q 2025

• Additional Data for Abpro Technology Platform • Additional Key Team Members Appendix • Additional Data for ABP-102(HER2/CD3) • Additional Data for ABP-201(VEGF/ANG2)

Additional Data for Abpro Technology Platform 31

32 32 Diversimmune Platform Case study: Amyloid*: Preclinical results from functional therapeutic antibodies ® generated with DiversImmune platform, via a project for GSK, 1 published in Nature and The New England Journal of 2 Medicine Abpro generated a therapeutic mAb “Abp1” against Amyloid used by GSK, featuring high affinity and specificity in ways other approaches can not Conformational epitope recognized by Abp1 (highlighted in black) *Amyloid plaques, composed of misfolded proteins, are a hallmark feature in the brains of individuals with Alzheimer's disease, contributing to the neurodegenerative process 1 https://www.nature.com/articles/nature09494 2 https://www.nejm.org/doi/full/10.1056/NEJMoa1504942

33 Neutralizing Antibody B cell Cloning Discovery Platform Timeline: < 2 months Neutralizing Target-specific Paired H/L cDNA NGS B Cell isolation Activity memory B cells by barcoding sequencing Convalescent /immunized human Humanized mice subjects A strategy to enrich only the B cells that Cloning are producing blocking antibodies is in Development nAb epitope Target-specific the works. Expression candidates binning Ig repertoire In-house reporter virus particle (RVP) Testing production capability makes it possible to test new emerging variants at any points as needed.

34 Anticipated Advantages of TetraBi Format Over First- and Second-Generation T-Cell Engagers nd st 1 Generation 2 Generation Abpro Antibody Bispecific Bispecific TetraBi Benefit Characteristics Stronger binding to the tumor cell, potentially leading Bivalent Binding to to increased efficacy and an expanded patient Tumor Antigen population Long Circulating Extends duration of therapeutic effect and reduces Half-life frequency of dosing Fc engineered to Decreases interaction with other immune cells, reduce CRS lowering risk of unwanted side effects Low Risk of Natural antibody sequences decrease risk of immune Immunogenicity response, which can lead to decreased efficacy Straightforward Symmetrical structure streamlines manufacturing by Manufacturing reducing risk of chain mispairing

Additional Key Team Members 35

36 Additional Key Team Members Askar Kuchumov, PhD Awo Kankam Shaun Murphy, PhD Mengsha Wang, MBA VP of Business VP of Clinical Operations; VP of Immunology Director of Corporate Development Head of Program Management Development Clark U MSc. Finance, MBA Lomonosov Moscow State, BS Cranfield UK, Brown PhD, Wayne State U School of Medicine, PhD MSc Research Harvard Medical School Lactocore (Interim CEO), Astrotide (Co- Bill & Melinda Gates Medical Joined Abpro in 2014 Joined Abpro in 2014 founder/CEO), Cleveland Biolabs Research Institute, Moderna, Previously at Toxikon (Director of BD) GSK, Novartis, AstraZeneca

Additional Data for ABP-102 HER2/CD3 T-Cell Engager 37

ABP-102: engineered TetraBi antibodies exhibit selectivity in vitro, with potent 38 cytotoxicity on HER2-high cell lines and reduced killing of HER2-low cell lines HER2 expression level High Intermediate Trastuzumab binding by flow cytometry results in a 1 range of HER2 expressing cancer cell lines. Low 1 (left panel) Abpro internal data; trastuzumab (1ug/mL) + anti-human IgG Fc specific PE; flow cytometry on BD FACSCelesta. 2 ABP-102 candidate molecules exhibit preferential killing of HER2-high (SKBR3, BT-474, (right panel) Abpro internal data; cytotoxicity of cell lines using PBMCs (10:1 E:T ratio) after 42 hours, readout by CellTiterGlo2.0 reagent NCI-N87) and HER2-intermediate (SKOV-3, HCC1954, MDA-MB-453) cell lines, with (Promega). 2 reduced cytotoxic activity on HER2-low cell lines (ZR-75-1, HT55, MCF-7, JIMT-1). Conclusion: ABP-102 candidate bispecific antibodies have potent cytotoxicity at similar levels as the parental non-affinity-tuned bispecific antibody on HER2-high and HER2-intermediate cell lines. On HER2-low cell lines, ABP102 candidates have reduced cytotoxicity, and exhibit more selectivity than the parental bispecific antibody, reducing the potential for “on-target, off-tumor” toxicity.

ABP-102: engineered TetraBi antibodies exhibit functional selectivity for T cell 39 activation, including reduced cytokine release for HER2-low expressing cell lines HER2 high HER2 low ABP-102-mediated PBMC cytotoxicity of HER2-high (SKBR3) ABP-102-mediated cytokine release (IL-2, IFNg, IL-6, TNFa) in supernatants with HER2-high target cells (SKBR3) is modestly reduced, 1 2 and HER2-low (MCF-7) cell lines. while for HER2-low (MCF-7) target cell lines, greater reductions in cytokine release are observed. Conclusion: ABP-102 engineered dual-arm affinity reduction strategy resulted in candidates with reduced cytokine release compared to the parental molecule, reducing the potential for “on-target, off-tumor” toxicity. 1 Abpro internal data; cytotoxicity of cell lines using PBMCs (10:1 E:T ratio) after 42 hours, readout by CellTiterGlo2.0 reagent (Promega). 2 Abpro internal data; cytotoxicity of cell lines using PBMCs (10:1 E:T ratio) after 42 hours, readout by bead-based multiplex assay for cytokine detection (R&D Systems/Luminex).

Additional Data for ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODIES 40

41 ABP-201 Exhibits Favorable PK Compared with Vabysmo 1 Faricimab(RG7716) 0.5 mg dose in Cyno PK parameter Unit Serum Aqueous C µg/ml 3.8 99 max t h 24 72 max t h 89.3 68 1/2 Faricimab PK in t h 672 672 last Cyno AUC (ug*h)/ml 295 18100 0-tlast AUC (ug*h)/ml 296 18200 0-inf F % 12.7 N/A vs. 2 ABP-201 0.2mg dose in Rabbit PK parameter Unit Serum Aqueous Vitreous Retina C µg/ml 0.415 14.374 183.357 8.457 max ABP-201 PK in T h 48 48 1 24 max t h 38 108 82 106 Rabbit 1/2 AUC (ug*h)/ml 52 2529 36922 1777 0-tlast AUC (ug*h)/ml 55 2557 37027 1795 0-inf MRT (h) 89 165 142 158 1 Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases [published correction appears in EMBO Mol Med. 2019 May;11(5). 2 Study contracted at ContractKinetica, LLC

42 ABP-201 Exhibits Favorable PK Compared with Eylea 1 ABP-201 0.2mg dose in Rabbit PK parameter Unit Serum Aqueous Vitreous Retina C µg/ml 0.415 14.374 183.357 8.457 max t h 48 48 1 24 max t h 38 108 82 106 1/2 AUC (ug*h)/ml 52 2529 36922 1777 0-tlast AUC (ug*h)/ml 55 2557 37027 1795 0-inf MRT (h) 89 165 142 158 1 Study contracted at ContractKinetica, LLC

43 Certain Risk Related to ACAB, Abpro and the Business Combination All references to the “Company,” “we,” “us” or “our” refer to the business of Abpro Corporation. and its subsidiaries, taken as a whole, unless the context otherwise requires. The risks noted below are not exhaustive and are qualified in their entirety by disclosures contained in future documents filed or furnished by the Company, Atlantic Coastal Acquisition Corp. II. (“ACAB”), the newly formed company that will become the parent company of the Company and ACAB (the “combined company” or “NewCo”) after the proposed business combination and the related transactions contemplated among the parties (collectively, the “Business Combination”), or others, with the U.S. Securities and Exchange Commission (the “SEC”). The risks presented in such filings will include risks with respect to the business and securities of the Company, ACAB, and Newco, as well as risks related to the Business Combination and any related financing, and may differ significantly from and be more extensive than those presented below. Certain risks related to ACAB, Abpro, and the Business Combination include the following: • ACAB’s and Abpro’s ability to complete the Business Combination during the anticipated timeframe or at all, including as a result of any changes in SEC regulations or policies related to business combinations involving SPACs that could adversely affect ACAB’s and Abpro’s ability to negotiate and complete the Business Combination; • Abpro’s success in retaining or recruiting, or changes required in, officers, key employees, or directors following the Business Combination; • The funds in the trust account being available to ACAB or the combined company; • ACAB’s or the combined company’s ability to obtain additional financing to complete the Business Combination; • ACAB’s public securities’ liquidity and trading and those of the combined company; • The lack of a market for ACAB’s or the combined company’s securities; • The use of funds not held in the trust account or available to ACAB from interest income on the trust account balance and the trust account not being subject to claims of third parties; • The impact of macroeconomic conditions and geopolitical crises; • The number of ACAB shareholders voting against the business combination proposal; • The occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; • The ability to achieve and maintain the listing of the combined company’s shares on a national securities exchange following the Business Combination; • Changes adversely affecting the businesses in which Abpro is engaged, including the risk that the Business Combination disrupts current plans and operations of the Company as a result of the announcement or the consummation of the Business Combination; • Management of growth and Abpro’s ability to execute on its business strategy and plans; • The result of future financing efforts; • Risks related to regulatory matters, including regulatory approvals and laws and regulations related to anti-corruption, cyber security and privacy; • Risks related to regulatory approval of Abpro’s current or future products and therapies and Abpro’s ability to successfully commercialize any these products and therapies in a timely manner or at all, as well as Abpro’s ability to accurately anticipate demand and efficacy for its products and therapies; • Abpro’s future financial performance, including the risk that Abpro’s financial results and business metrics are likely to fluctuate on a quarterly and annual basis; • Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate; • Risks related to Abpro’s ability to retain and expand its development agreements, the lack of long-term and binding commitments with co-developers, and its ability to compete effectively; • Risks related to international operations and related regulatory risks; • Risks related to our intellectual property, including our ability to protect our IP portfolio and risks related potential claims by third parties; • Abpro’s failure to raise additional capital or generate the significant capital necessary to maintain and expand its operations, and risks related to Abpro’s ability to continue as a “going concern”; • Abpro’s ability implement and maintain sufficient internal controls over financial reporting and disclosure controls and procedures, and its ability to report its financial results in an accurate and timely manner; • Fluctuations in the stock price of the combined company’s securities; • Any projections will not have been prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants, and have not been compiled or examined by any registered public accountants nor any other independent expert or outside party; • Risks related to the limited public company experience among Abpro’s management team and risks related to Abpro’s ability to operate as a public company and comply with applicable law and regulations and corporate governance matters applicable to public companies, including those required by the SEC and applicable stock exchange; • Certain of ACAB’s and Abpro’s directors and officers and significant stakeholders may have interests in the Business Combination different from the interests of ACAB’s or Abpro’s shareholders; • The exercise of discretion by directors and officers ACAB or Abpro in agreeing to changes to the terms, or waivers of closing conditions, in the definitive agreements with respect to the Business Combination and potential conflicts of interest of SPAC’s sponsor, directors and officers; and • Costs related to the Business Combination and the increased costs of being a public company following the consummation of the Business Combination.

Mission: Developing antibody therapies to improve the lives of patients Thank you! facing severe and life- threatening diseases https://abpro.com/ IR@abpro.com ABPRO CORPORATION 68 Cummings Park, Woburn, MA 01801